GALECTIN THERAPEUTICS INC 10-Q

Item 5. Other Information Not Applicable Item 6. Exhibits Exhibit Number Description of Document Note Reference 31.1* Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 31.2* Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 32.1** Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 The following financial statements and footnotes from the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2022 formatted in Inline Extensible Business Reporting Language (Inline XBRL): 101.INS Inline XBRL Instance Document** 26 Table of Contents Exhibit Number Description of Document Note Reference 101.SCH Inline XBRL Taxonomy Extension Schema Document** 101.CAL Inline XBRL Taxonomy Calculation Linkbase Document** 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document** 101.LAB Inline XBRL Taxonomy Label Linkbase Document** 101.PRE Inline XBRL Taxonomy Presentation Linkbase Document** 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101)** * Filed herewith. ** Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. 27 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 15, 2022. GALECTIN THERAPEUTICS INC. By: /s/ Joel Lewis Name: Joel Lewis Title: Chief Executive Officer and President (principal executive officer) By: /s/ Jack W. Callicutt Name: Jack W. Callicutt Title: Chief Financial Officer (principal financial and accounting officer) 28